|
Women
|
55 (33)
|
119 (33)
|
1.00
|
|
Men
|
110 (67)
|
238 (67)
|
1.00
|
|
Age, mean (± SD); median (25th and 75th percentiles)
|
41.6 (11.9); 44 (31, 50)
|
64.3 (16.4); 67 (56, 76)
|
< 0.01
|
|
Predisposing factors
|
|
Bicuspid aortic valve
|
0 (0)
|
20 (6)
|
< 0.01
|
|
Prosthetic valve
|
12 (7)
|
83 (23)
|
< 0.01
|
|
CIED
|
2 (1)
|
38 (11)
|
< 0.01
|
|
Rheumatic heart disease
|
0 (0)
|
2 (1)
|
1.00
|
|
Congenital heart disease
|
0 (0)
|
8 (2)
|
0.06
|
|
History of IE
|
49 (30)
|
34 (10)
|
< 0.01
|
|
Known valvular disease
|
3 (2)
|
78 (22)
|
< 0.01
|
|
Heart failure before or under IE treatment
|
19 (12)
|
45 (13)
|
0.72
|
|
Patients fulfilling Duke’s major criteria
|
|
Blood culture positive for IE
|
144 (87)
|
304 (85)
|
0.78
|
|
Echocardiography positive for IEa
|
165 (100)
|
287 (80)
|
< 0.01
|
|
Patients fulfilling Duke’s minor criteria
|
|
Fever
|
150 (91)
|
304 (85)
|
0.07
|
|
Vascular phenomena
|
101 (61)
|
120 (34)
|
< 0.01
|
|
Spondylitis
|
25 (15)
|
30 (9)
|
0.02
|
|
Pulmonary septic emboli
|
55 (33)
|
11 (3)
|
< 0.01
|
|
New heart murmur
|
20 (12)
|
63 (18)
|
0.11
|
|
Immunological phenomenon
|
2 (1)
|
19 (5)
|
0.03
|
|
Outcomes
|
|
Surgery
|
27 (16)
|
121 (34)
|
< 0.01
|
|
In-hospital mortality
|
7 (4)
|
27 (8)
|
0.15
|
|
Relapse during follow upb
|
1 (0)
|
4 (1)
|
1.00
|
|
Re-infected during follow upb
|
2 (1)
|
1 (0)
|
0.24
|
